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N4N43,4-dihydro-2-methyl-4-oxoquinazolin-6ylmethyl)-Nmethylamino}2-thenoyl)-L-glutamic acid (ZD1694; Tomudex) is a potent thymidylate synthase (TS; EC 2.1.1.45) inhibitor (Jackman et al., 1991a,b; Marsham et al., 1991) which has successfully completed European phase I (Clarke et al., 1994) and phase II clinical studies (Burris et al., 1994; Gore et al., 1994; Smith et al., 1994; Zalcberg et al., 1994) . ZD1694 was designed as a non-nephrotoxcic, highly potent analogue of N'0-propargyl-5,8-dideazafolic acid (CB3717; Jones et al., 1981) which was active in phase I/II studies, particularly in breast tumours, hepatomas and platinum-refractory ovanan cancer Clarke et al., 1993) . CB3717 was withdrawn from further study because of dose-limiting nephrotoxicity, a feature overcome, in mouse models, by the synthesis of more water-soluble analogues (Jones et al., 1989; Hughes et al., 1990; Jackman et al., 1990 , 1991c , Marsham et al., 1991 . Many of these new compounds showed improved substrate activity for the reduced folate/methotrexate cell membrane transport carrier protein (RFC) and folylpolyglutamate synthetase (FPGS), rendering them potent as cytotoxic agents (Jackman et al., 1991d) . Polyglutamates of ZD1694 rapidly accumulate within the cell and studies have confirmed these to be the cytotoxic species (Jackman et al., 1991a , 1993a , Ward et al., 1992 Gibson et al., 1993) . For example, a major metabolite, the tetraglutamate, is a 60-fold better TS inhibitor (K = 1 nM) than the parent drug and is not readily effluxed from cells. In combination, these properties explain why ZD1694, although a 20-fold poorer inhibitor of isolated TS, is 500-fold more cytotoxic than CB3717.
The pyrrolopyrimidine, LY231514, is another TS inhibitor currently in phase I clinical study and shares many of the properties of ZD1694 (Grindey et al., 1992) , whereas BW1843U89, a benzoquinazoline, is unusual in that it has supenor affinity for the human than for the murine RFC and cannot be metabolised by FPGS beyond the diglutamate (Duch et al., 1993) . The interaction of such folate-based TS inhibitors with the RFC and FPGS provides an opportunity for the design of novel agents that are not substrates for one, or both, of these proteins. Such compounds may express a different anti-tumour or toxicity profile. Intrinsic or acquired resistance due to reduced levels or altered expression of the RFC or FPGS would be expected to be overcome by such compounds. AG337 is such an example. It is a lipophilic TS inhibitor (in phase I study) which is believed to diffuse into cells and is structurally precluded from polyglutamation (Webber et al., 1993) . Our own studies have identified a series of highly lipophilic benzylamide analogues of 2-desamino-2-methyl-N'0-propargyl-5,8-dideazafolic acid (ICI 198583 ) with good in vitro activity (Barker et al., 1991; Skelton et al., 1994) . However, we have realised greater in vivo activity in mice with water-soluble compounds that use the RFC for cell entry but which are not substrates for FPGS. Structural modifications of ICI 198583 which produce this profile include methylation of the 7-position of the quinazoline ring and the replacement of glutamate with either natural or unnatural amino acids (Barker et al., 1991 , and manuscript in preparation) or dipeptides (Bavetsias et al., 1993; Jackman et al., 1993b) .
To aid the understanding of potential resistance mechanisms to ZD1694 that may occur in man. and the development of TS inhibitors that may overcome such resistance, requires the establishment of a panel of in vitro tumour cell lines with defined resistance mechanisms. Four cell lines, the L1210 mouse leukaemia, the W1L2 human lymphoblastoid and two human ovarian (CHI and 41M) cell lines, were exposed to increasing concentrations of ZD1694 until they were established in 1-5Mm of the drug. A range of techniques was used to define the resistance mechanism(s) in each cell line. These included measurement of TS enzyme activity and protein levels, ITP and dUMP concentrations, uptake and polyglutamation of the drug, and cross-resistance studies to antifolates with known mechanisms of action. Two of the . The human ovarian CHl and 41M (Hills et al., 1989) (-14 h), W1IL2 (-18 h), W IL2:R"'6 (-20 h), CH1I (-18h), CH1:RDl6 (-18h), 41M (-28 h) and 41M: RD" (-28h) .
TS activity, TS enzyme-linked immunosorbent assay and FPGS TS activity was measured by 3H release as described previously . For the measurement of CHI ovarian tumour TS kinetic parameters, enzyme was partially purified and assayed as previously described . The use of mixed diastereoisomers of 5, 1O-methylene tetrahydrofolate 15,10-CH2FH4(6R,S)J rather than the pure 6R does not affect the analysis, although the K. values are twice the 6R value (Ward et al., 1992) . The values of the kinetic parameters, K and K., which are the dissociation constants for I from IE (TS.dUMP.I) and IES (TS.dUMP.5, lOCH2FH4.I) complexes, respectively, were determined for ZD1694 and its triglutamate by multivariate non-linear regression in which measured velocities were fitted to different rate equations (Ward et al., 1992 (Curtin et al., 1991) , the ribonucleotides were destroyed using sodium periodate. TTP pools were measured directly on aliquots of the extract using a radioimmunoassay (RIA) sensitive to -I pmol 10-6 cells. An RIA for dUTP (Piall et al., 1989) was adapted to estimate 'immunoreactive' deoxyuridine nucleotides (mainly dUMP) in the same cell extracts by utilising the cross-reactivity of the antiserum to dUDP and dUMP (Raynaud et al., 1993) . The sensitivity of this assay was also -I pmol 10-6 cells. All RIAs were performed in duplicate at three dilutions of the extracts. (Figure 3a) . The levels of the parent monoglutamate and its polyglutamate forms were all reduced in the resistant cell line. However, the predominant metabolite was the tnglutamate in both cell lines. These data are consistent with a reduced rate of membrane transport of ZD1694 in the resistant cells. The intracellular pool of ZD1694 (particularly the triglutamate) could be increased by raising the extracellular concentration to 1 FLM. (Figure 3b) (Jackman et al., 1991c) . Again the L1210:RDIlM cells were unable to form polyglutamates, with 98% of the cellular 3H-labelled material (total = 2.6 pzM) being identified as parent drug (data not shown).
After 24 h exposure to 0.1 SIM (3H]ZD1694, significant intracellular accumulation was found in WlL2:RDl16 cells (-3 x W1L2 parental line). Most was parent drug (28%) or diglutamate (62%) (Figure 3c ). In parental W1L2 cells only 1% and 2% of the drug was in these forms, the vast majority being tetra-and pentaglutamates.
The TS-overproducing cell line, CHi:RDlR4, did not accumulate a significantly higher level of ZD1694 when compared with parental cells. However, there was, at 4 and 24 h, a shift to a greater proportion in the mono-to triglutamate form in the resistant cells. The significance of this result is difficult to interpret (Figure 3d ).
Cross-resistance studies
The structures of the quinazoline TS inhibitors, together with their TS inhibitory activity and FPGS substrate activity, are given in Table IV . Results indicating their use of the RFC is indicated in Tables V-VHI, and details WlL2:RDlW cells were highly cross-resistant to all quinazoline, pyrrolopyrimidine (LY231514) and benzoquinazoline (BW1843U89) TS inhibitors, consistent with their high expression of TS (Table V) . Lower cross-resistance was seen to the lipophilic analogue, 10, which possibly relates to a second locus of action becoming important to growth inhibition at the higher compound concentration. No cross-resistance was (Jackman et al., 1991acA 1993a Marsham et al., 1991; Boyle et al., 1993; Duch et al., 1993; Pavlovic et al., 1993; Webber et al., 1993 (Table VI) . The 2.4 cross-resistance to AG337 may relate to its poor activity against the parental line (9.3 tIM) with the possibility of another locus becoming significant at the higher concentration used against the resistant cells. No significant cross-resistance was seen to inhibitors of other folate-dependent enzymes, e.g. MTX, trimetrexate or Lometrexol. The pattern of cross-resistance to the antifolates was very different in the other two cell lines, and the results are crucial in explaining the mechanisms of resistance involved. This is because the data separating transport from an FPGS defect were not definitive (see above). The 41M:R D1694 cells were only cross-resistant to compounds (whatever the target enzyme) known to use the RFC, although the degree of cross-resistance varied widely (6-to 264-fold) ( Table VII) .
The L1210:RDl9 cell line produced cross-resistance results that can all be explained as a consequence of defective polyglutamation (Table VIII) . High cross-resistance was observed to the thiazole derivative of ZD1694 (3) and to 7, both very good FPGS substrates (K.= 1.0 and 6.4 liM respectively) (Jack-man et al., 1991d). The degree of cross-resistance to other analogues was lower, and was again consistent with their reduced potential to form intracellular polyglutamates.
Thus, ICI 198583 with a relatively high K. for FPGS (40 gM) is less extensively polyglutamated in L1210 cells than ZD1694 (Jackman et al., 1991c) . No significant cross-resistance was seen to all antifolates known to be non-substrates for FPGS and that do not use the RFC, i.e. 10, AG337 and trnmetrexate. Similarly no cross-resistance was observed to FdUrd. Non-polyglutamatable compounds that use the RFC (e.g. 6, 8 and 9 and other unpublished examples) have cross-resistance values (2-3) significantly greater than 1, consistent with the small transport defect in the resistant line described above. A very low level of cross-resistance was observed to CB3717, MTX and aminopterin (2-to 3-fold). However a higher level of resistance (15-fold) was demonstrated to MTX if the drug exposure period was limited to 6h (data not shown). Indirect evidence supports polyglutamation of natural folates occumng normally in the L1210:RDl" cells.
The addition of 5 jAM leucovorin to cell cultures containing FdUrd resulted in a significant enhancement in growth inhibition (-2.5-fold) in both lines (data not shown). This is a well-recognised synergistic combination since stable ternary complex formation is promoted by elevating the 5,10-CH2FH4 pool with leucovorin. Similarly, when leucovorin (5 pM) was used to protect against the activity of the DHFR inhibitor, trimetrexate, both sensitive and resistant L1210 cells were protected to the same degree (-20-fold Although the cell lines were adapted to grow in 1-S5JM ZD1694, two of the resistant cell lines (WIL2 and L1210) were highly resistant, even -when challenged with 100 1M ZD1694. Consistent with TS inhibition, all parental cells had depletion of TTP and elevation of 'dUMP' pools following incubation for 4 h with growth-inhibitory concentrations of ZD1694. These pools were either not, or minimally, disturbed when L1210 or W1L2 resistant cells were exposed to 50JM ZD1694, demonstrating that TS operates relatively normally under these conditions. This would be expected from the high level of resistance described above. The two resistant ovarian lines, particularly the CH1:RD1694 line, showed disturbances in pool size at much lower concentrations consistent with their lower levels of resistance.
Two of the human cell lines, Wl L2 and CH1, had significantly elevated TS activity (500-and 4-fold respectively). TS protein levels were similarly increased when determined by ELISA (Table I) . Immunoblotting demonstrated a similar increase, and this was accompanied by a 100-and 2-to 3-fold increase in TS gene copy number and mRNA respectively (Freemantle et al., 1993) . The human ovarian cell line, CHI, has a low level (14-fold) of ZD1694 resistance, and here the resistance is generally consistent with the small elevation in TS activity (levels (O'Connor et al., 1992) . The lower level of cross-resistance to quinazoline TS inhibitors that are not substrates for FPGS, e.g. 9 and 10, is therefore expected. Sensitivity to the DHFR inhibitors (MTX and trimetrexate) and the GARTF inhibitor (Lometrexol) is completely consistent with TS overproduction being the only alteration in the WIL2:RD1694 cells. Sensitivity to FdUrd is explained by sequestration of the 5,10-CH2FH4 pool into the ternary complex with TS (in large excess) and FdUMP, resulting in inhibition of TS and other folate-dependent enzymes through substrate depletion. This is why supplying the cell with folinic acid, which reinstates de novo purine and TMP synthesis by replenishment of the reduced folate pool, allows resistance to FdUrd to be revealed. We have previously recorded this phenomenon in other cell lines with amplified TS genes O'Connor et al., 1992) .
Gene amplification leading to increased TS expression as a mechanism of experimental resistance to pyrimidine-based (FdUrd) (Baskin et al., 1975; Priest et al., 1980; Rossana et al., 1982; Berger et al., 1985; Jenh et al., 1985) or folatebased TS inhibitors has been previously reported Iman et al., 1987; Danenberg and Danenberg, 1989; O'Connor et al., 1992) . There is also evidence that this can occur in man in response to treatment with 5-FU (Clark et al., 1987) . The introduction of new antifolates, targeted towards TS, into the clinic may establish whether this will be a common resistance mechanism in man.
The second human ovarian 41M line (-100-fold resistant to ZD1694) appears to have a primary defect, which is reduced drug uptake via the RFC. A consequence of lower intracellular level of the parent drug is a substantially reduced concentration of the more active intracellular polyglutamates. Thus, the cross-resistance seen to antifolates known to use the RFC, including those with targets other than TS, was expected. CB3717 uses this carrier poorly (as determined in L1210 cells) (Jackman et al., , 1993a , while the lipophilic compounds AG337 (Webber et al., 1993) and trimetrexate (Fry and Jackson, 1986) do not use it at all, and of course FdUrd uses a nucleoside transport mechanism. All of these compounds retained activity in the resistant cells. The very high cross-resistance seen to BW1843U89 may relate to the excellent affinity this compound has for the human RFC (Duch et al., 1993) . Transport defects have frequently been reported as a mechanism of resistance to MTX (Fry and Jackson, 1986) . Defective transport is also commonly associated with other resistance mechanisms, including a reduced ability to form or maintain polyglutamates of MTX or Lometrexol (Cowan and Jolivet, 1984; Assaraf et al., 1992; Koizumi and Allegra, 1992; Rhee et al., 1993) .
The importance of polyglutamation in the action of antifolates such as MTX and Lometrexol has led to the recent description of several cell lines with intrinsic or acquired resistance due to a reduced accumulation of polyglutamate species (Pizzorno et al., 1988 (Pizzorno et al., , 1989 McCloskey et al., 1991; Van der Laan et al., 1991; Li et al., 1993; Pavlovic et al., 1993) . Considering the importance of polyglutamate formation for the cytotoxicity of ZD1694 (Jackman et al., 1991a (Jackman et al., , 1993a AL Jackman et a 922 to ZD1694, and its elevation could be a potential resistance mechanism.
The results of the cross-resistance studies support a polyglutamation defect, as only TS inhibitors, active through polyglutamation, had significantly reduced activity against the L1210 resistant cells. Some apparent anomalies do exist but can be explained including the low level of crossresistance to CB3717 (3-fold) or to the pteridine-based DHFR inhibitors, MTX and aminopterin (2-to 3-fold). CB3717 does form polyglutamates in L1210 cells, but relatively slowly. For example, after incubation with equitoxic concentrations of ZD1694 (0.1 gM) and CB3717 (50 gM) for 4 or 6 h respectively, 98% of D1694 and only 15% of CB3717 was measured as polyglutamates (Sikora et al., 1988; Jackman et al., 1991a ). CB3717's lower dependence on polyglutamate formation for activity, in addition to the slightly lower cross-resistance expected from a compound that does not use the RFC (small transport defect, see above), prob ably explains the low cross-resistance observed. A lower requirement for polyglutamation may partially explain the good activity of MTX and aminopterin in the resistant cells (MTX is poorly polyglutamated at low intracellular concentrations). Furthermore, the polyglutamates of DHFR inhibitors, unlike the quinazoline TS inhibitors, are not significantly more potent as inhibitors of their target enzyme (Szeto et al., 1979; Chabner et al., 1985) than the parent monoglutamate, and the importance of their formation lies in their drug retentive properties (Galivan, 1980; Jolivet and Chabner, 1983) . Thus, under continuous drug exposure conditions, the lack of polyglutamate formation is not particularly deleterious, however under short exposure conditions (6 h), when drug retention is important, MTX was -15-fold less active in the resistant than in the L1210 parental line. Similarly, the TS inhibitor BW1843U89 has similar activity against TS in either the parent monoglutamate or diglutamate form (Duch et al., 1993) and may therefore account for the low level of cross-resistance to this agent.
The acquisition of these four ZD1694-resistant cell lines has confirmed the importance of TS, the RFC and polyglutamation for the activity of the drug. Clearly, it is likely that certain tumours may intrinsically possess or acquire these phenotypes. However, as more antifolates are developed for clinical study with differing target enzymes, transport and metabolic properties, it will be possible to overcome these resistance mechanisms. This panel of resistant cell lines has aided the development of quinazoline TS inhibitors that are not metabolised by FPGS but still require cellular uptake via the RFC and are currently being used to identify compounds whose activity is independent of either process. This work was supported by the Cancer Research Campaign, UK.
